End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4,674 MXN | +6.63% | +10.49% | -5.29% |
05:14pm | Roche: efficacy of Evrysdi in spinal muscular atrophy | CF |
05:12pm | Roche's Five-year Data Confirms Efficacy, Safety of Evrysdi Drug for Spinal Muscular Atrophy in Children | MT |
Sales 2024 * | 60.39B 67.34B 1,236B | Sales 2025 * | 63.83B 71.18B 1,306B | Capitalization | 196B 219B 4,015B |
---|---|---|---|---|---|
Net income 2024 * | 13.27B 14.8B 272B | Net income 2025 * | 14.76B 16.46B 302B | EV / Sales 2024 * | 3.48 x |
Net Debt 2024 * | 13.77B 15.36B 282B | Net Debt 2025 * | 7.88B 8.79B 161B | EV / Sales 2025 * | 3.2 x |
P/E ratio 2024 * |
14
x | P/E ratio 2025 * |
12.7
x | Employees | 103,605 |
Yield 2024 * |
4.11% | Yield 2025 * |
4.23% | Free-Float | 88.91% |
Latest transcript on Roche Holding AG
1 day | +6.63% | ||
1 week | +10.49% | ||
Current month | +6.63% | ||
1 month | +16.85% | ||
3 months | +4.81% | ||
6 months | -6.91% | ||
Current year | -5.29% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 95-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 4,674 | +6.63% | 245 |
24-05-31 | 4,383 | +3.62% | 355 |
End-of-day quote Mexican S.E., June 05, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.82% | 754B | |
+40.95% | 630B | |
-6.16% | 352B | |
+19.86% | 331B | |
+9.32% | 298B | |
+18.45% | 250B | |
+11.88% | 217B | |
+5.90% | 164B | |
-0.73% | 163B |
- Stock Market
- Equities
- ROG Stock
- ROG N Stock